Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

Stocktradesmoon May. 13 at 6:10 PM

$ABCL $ABCL "If you listen to others, not just on public markets but in your life, you will be blown off course. Having conviction and staying the course, I think, is probably the big thing." - Carl Hansen

0 · Reply

Stocktradesmoon May. 13 at 5:40 PM

$ABCL $ABCL AbCellera collected the first $18 million of their $36 million litigation settlement with Bruker in Q1 2026, with the remaining $18.0 million expected in Q2. (Source: 10Q)

0 · Reply

tradersunion353 May. 13 at 5:23 PM

$ABCL Stay away from that clown DEMAM he comes up with all different narratives every time stock drops.. POS is crashing like there is no tomorrow every since ph1 data is release. whats bullish is in this?

0 · Reply

Ed_Ng May. 13 at 5:04 PM

$ABCL $ABCL no they don't do anything. They just have been trying begging people with hopium they will buy, the SP is pump, so they can exit their heavy bags

0 · Reply

tradersunion353 May. 13 at 4:49 PM

$ABCL pumpers aka married to $ABCL clowns how is adding and loading working after ph1 data and stock crashing

0 · Reply

Stocktradesmoon May. 13 at 4:45 PM

$ABCL Bought some more $ABCL on the dip today. I am convinced this goes to $6 at the end of the month

0 · Reply

Ed_Ng May. 13 at 3:40 PM

$ABCL lol. 3 coming fast

0 · Reply

DeMampCamp May. 13 at 2:06 PM

$ABCL Even if you're here for only a quick trade, if you LIKE MONEY you'd play the gap fill to $5.24 at the very minimum....hopefully it doesn't stop there, but anyone selling right now is likely an emotional trader, which doesn't work out in the long run! Cheers all!

1 · Reply

tradersunion353 May. 13 at 1:57 PM

$ABCL pos tanking like there is no tomorrow yes clowns aka who are married to this pos will come out like maggots and start cheerleading.. clowns

0 · Reply

tradersunion353 May. 13 at 12:54 PM

$ABCL hello ! pos dropped in p1 data what are you guys cheerleading and celebrating for clowns? and thet DEMEM guy .. 🥊 to him for pumoung this pos and stock going nowhere

0 · Reply

AbCellera price target raised to $8 from $7 at Stifel

2026-05-11T21:58:40.000Z - 1 day ago

AbCellera Biologics options imply 9.7% move in share price post-earnings

May 11, 2026, 5:00 PM EDT - 1 day ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 4:05 PM EDT - 1 day ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 5 days ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

2026-05-05T10:36:31.000Z - 8 days ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

Apr 21, 2026, 1:30 PM EDT - 22 days ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 23 days ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

2026-04-09T20:10:26.000Z - 4 weeks ago

AbCellera initiated with a Buy at JonesResearch

Apr 1, 2026, 4:05 PM EDT - 5 weeks ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 2 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 2 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

2026-02-24T21:15:21.000Z - 2 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

Feb 24, 2026, 4:05 PM EST - 2 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 3 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 4 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T14:36:23.000Z - 4 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

Jan 12, 2026, 9:00 AM EST - 4 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

2025-12-18T14:20:19.000Z - 5 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

Dec 18, 2025, 9:00 AM EST - 5 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 5 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 5 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 6 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 6 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

2025-11-07T11:16:20.000Z - 6 months ago

AbCellera downgraded to Market Perform from Outperform at Leerink

Nov 6, 2025, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

2025-09-10T13:20:54.000Z - 8 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX

Sep 10, 2025, 9:07 AM EDT - 8 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 8 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

2025-08-27T13:20:26.000Z - 9 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 9 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

2025-08-08T13:26:29.000Z - 9 months ago

AbCellera price target raised to $7 from $5 at BMO Capital

Aug 7, 2025, 5:00 PM EDT - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 9 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

2025-07-07T10:40:33.000Z - 11 months ago

AbCellera assumed with an Outperform at Leerink

2025-06-11T13:45:23.000Z - 1 year ago

Unusually active option classes on open June 11th

AFRM BILI FXE LAES PCG QUBT RGTI

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

2025-05-30T17:05:30.000Z - 1 year ago

AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 17, 2024, 11:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 16, 2024, 10:00 AM EDT - 2 years ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 20, 2024, 11:15 AM EDT - 2 years ago

AbCellera Biologics Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Stocktradesmoon May. 13 at 6:10 PM

0 · Reply

Stocktradesmoon May. 13 at 5:40 PM

$ABCL $ABCL AbCellera collected the first $18 million of their $36 million litigation settlement with Bruker in Q1 2026, with the remaining $18.0 million expected in Q2. (Source: 10Q)

0 · Reply

tradersunion353 May. 13 at 5:23 PM

0 · Reply

Ed_Ng May. 13 at 5:04 PM

$ABCL $ABCL no they don't do anything. They just have been trying begging people with hopium they will buy, the SP is pump, so they can exit their heavy bags

0 · Reply

tradersunion353 May. 13 at 4:49 PM

$ABCL pumpers aka married to $ABCL clowns how is adding and loading working after ph1 data and stock crashing

0 · Reply

Stocktradesmoon May. 13 at 4:45 PM

$ABCL Bought some more $ABCL on the dip today. I am convinced this goes to $6 at the end of the month

0 · Reply

Ed_Ng May. 13 at 3:40 PM

$ABCL lol. 3 coming fast

0 · Reply

DeMampCamp May. 13 at 2:06 PM

1 · Reply

tradersunion353 May. 13 at 1:57 PM

$ABCL pos tanking like there is no tomorrow yes clowns aka who are married to this pos will come out like maggots and start cheerleading.. clowns

0 · Reply

tradersunion353 May. 13 at 12:54 PM

$ABCL hello ! pos dropped in p1 data what are you guys cheerleading and celebrating for clowns? and thet DEMEM guy .. 🥊 to him for pumoung this pos and stock going nowhere

0 · Reply

Stocktradesmoon May. 13 at 12:39 PM

$ABCL Carl Hansen speaks at Bank of America today at 5pm Pacific on behalf of $ABCL Here’s where you can register to watch what he has to say. https://bofa.veracast.com/webcasts/bofa/healthcare2026/68O4bb.cfm This is the first conference after part of the abcl635 Phase 1 data has been released so it will be interesting to see how he incorporates that into the discussion. I’ll be listening. Good luck AbCellerites!

0 · Reply

Stocktradesmoon May. 13 at 12:37 PM

$ABCL TD Waterhouse Canada Inc became an $ABCL top-10 holder in Q1. Bought 9.5M+ shares.

1 · Reply

CPAADVANCED May. 13 at 10:08 AM

$ABCL The interesting thing about this company is that they have developed an engine that can produce drug candidates faster and with a higher chance of success. As with any pharma, drug candidates can look promising and still fail at latter phases. If the first few drugs pan out this could be a monster of a stock in the Regeneron type price. There is also the possibility of another "covid" coming along that would this time be developed internally and the entire revenue could flow back to ABCL. The institutions see the possibilities here and are increasingly getting on board. Great stock to buy and tuck away for the next 5 years as this plays out IMO.

0 · Reply

snowPOW May. 13 at 7:27 AM

$ABCL $BB exactly, this is social media and should be treated as such. The analysts that print stories up or down only benefits themselves like a car salesman and should be trusted equally to random posters. Fiduciary duty matters! Understand who has to give it to you and who doesn't. Analysts and social media posters certainly don't have it!

0 · Reply

snowPOW May. 13 at 7:18 AM

$ABCL underlying asset improves and share price goes down... That's not weird to you?

2 · Reply

Warbucks007 May. 13 at 4:51 AM

$ABCL I gave some crap to the pumpers going not stop about a year ago. Trimmed my position then but still have a decent position. Company is executing. We are still a ways away from running up. Temp check on the board is the shorts seem desperate. Pumpers still at it. We got time. Carl will lead this through. Hold for the prize. Not a bad time to add for the rise that will come in another few years

0 · Reply

Stocktradesmoon May. 13 at 2:15 AM

$ABCL More Upgrades

0 · Reply

Stocktradesmoon May. 13 at 12:43 AM

$ABCL I bought more $ABCL today at the open... and again at the close 😆

0 · Reply

tradersunion353 May. 13 at 12:41 AM

$ABCL SICK board.. folks here has been constantly celebrating every time stock drops stock has been down for last 5 years... POS is down on Ph1 data... Sick mentality

1 · Reply

Stocktradesmoon May. 13 at 12:04 AM

$ABCL To follow up on this. Looks like shorts covered about 3m shares as of the end of April. Still over 44m shares short on $ABCL . I’ll be curious to see where this trends now that we have positive phase 1 data out. And huge volume today. Nearly 17m shares traded. Institutions are officially joining the party. Will be interesting to see what updated institutional holdings are moving forward.

1 · Reply

TradeWinner May. 12 at 10:40 PM

$ABCL if anyone thinks the post on here move a stock up or down they are delusional. Almost 17 million shares today is not retail. But bodes well!!!

2 · Reply

HeIsHavingHisBath May. 12 at 9:22 PM

$ABCL Oh, look, the bot pumpers like each other's posts too to make legit investors think there's crowd support to their fluffing.

1 · Reply

Market Cap	1.60B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	4,400,995
Avg Vol	5,114,992
Day's Range	N/A - N/A
Shares Out	305.27M
Stochastic %K	62%
Beta	1.02
Analysts	Strong Sell
Price Target	$9.14